Organic Active Ingredients TRIZ Cases

A pemetrexed sodium salt formulation uses freezing and degassing to remove dissolved oxygen.

A zinc L-carnosine chelate combination inhibits viral propagation and replication within host cells.

CYP7B1 inhibitors enhance colony-forming cell yield by rescuing mobilization failures in sickle cell patients.

ABTL0812 polyunsaturated fatty acid derivative enhances cancer treatment efficacy through synergistic pharmaceutical combinations.

Exosomes deliver STING agonists and IL-12 to tumors, reducing systemic inflammation while enhancing therapeutic efficacy.

Urolithin A modulates mitochondrial membrane potential in haematopoietic stem cells to improve engraftment capacity.

Base-labile crosslinkers enable controlled release of therapeutic agents at target sites, reducing systemic toxicity and improving dosing convenience.

Aqueous condensation synthesizes imatinib base, eliminating toxic solvent waste and simplifying purification for industrial scale.

Chromatographic separation of S-1-propenylcysteine isomers achieves high trans-isomer content, treating hypertension without side effects.

Escalating uricase doses acclimate patients, preventing hypersensitivity reactions during gout therapy.

A process for preparing pexidartinib uses a Group 10 transition metal catalyst with water to form the target compound.

A variant activin IIB receptor polypeptide uses targeted amino acid substitutions to bind myostatin, activin A, and GDF-11 ligands.

Oxy133 oxysterol activates Hedgehog signaling to drive osteogenic differentiation, avoiding rhBMP-2 seroma formation.

Neuropeptide S receptor antagonists modulate anxiety and sleep patterns without causing sedation or dependence.

Radiation activates caspase to cleave the prodrug, releasing the drug at the tumor site while sparing normal cells from toxicity.

Optimized lipid emulsion formulations balance DHA, EPA, and ARA concentrations to reduce liver damage while improving fatty acid profiles in pediatric patients.

Layered enteric and sustained coatings delay gastric release, solving compliance issues from rapid absorption.

3-Deoxyanthocyanidins absorb blue light to shield retinal pigment epithelium cells from phototoxic damage.

Selective inhibition of PDE4B and PDE4D subtypes by a pyridino-oxopyridazine derivative reduces emesis while maintaining therapeutic efficacy.

Segmented saRNA structures target transcripts to resolve therapeutic efficacy and duration trade-offs.

Intranasal dendrimer nanoformulations deliver RNA interference agents to reduce tauopathy and neuroinflammation in Alzheimer's disease.

Viscous gel protects esophageal mucosa from acid reflux, addressing patient nonresponsiveness to standard therapies.

Gold nanoparticles functionalized with oligonucleotides enhance hybridization efficiency, overcoming low transfection stability in diverse cell types.

Meldonium orotate reduces infarct size and eliminates lethal arrhythmia outcomes by transforming the parent compound into a superior therapeutic salt.

Stable crystalline DHODH inhibitor polymorph characterized by specific X-ray powder diffraction peaks.

Non-aqueous solvents and molecular sieves stabilize cyclophosphamide, preventing hydrolytic degradation while enabling safe parenteral administration.

Pyridine-based inhibitors target CYP3A4 specifically to slow drug metabolism without causing liver injury or off-target side effects.

A swallowable capsule delivers therapeutic agents directly into the intestinal wall using a pH-responsive actuator mechanism.

Hydrophilic lozenges improve cannabinoid solubility and bioavailability while minimizing THC psychoactivity.

A microautophagy-enhancing agent increases lysosomal association-dissociation events to degrade lipid substrates.

Electrospun bioerodible implants eliminate surgical removal by degrading naturally after releasing drugs over prolonged periods.

Combines a manganese-based pentaaza macrocyclic ring complex with ascorbic acid derivatives to generate intracellular hydrogen peroxide.

Substituted indole ether compounds inhibit Toll-like receptor 7, 8, and 9 signaling to treat inflammatory diseases with improved stability.

A hypromellose capsule combines lithium orotate with L-leucine to enhance cognitive performance.

IRE1 kinase inhibitors block FMRP phosphorylation to restore cholesterol efflux and efferocytosis, reducing atherosclerotic lesion progression.

Vidofludimus inhibits dihydroorotate dehydrogenase, resolving toxicity and short half-life trade-offs in antiviral treatments.

Sublingual tocotrienol delivery bypasses hepatic first-pass metabolism and alpha-tocopherol competition, significantly increasing bioavailability.

Modified pyrrolo[2,3-d]pyrimidine scaffolds overcome drug resistance in hematological malignancies by enhancing cytotoxicity against resistant cell lines.

Non-aqueous deep eutectic solvents stabilize poorly soluble APIs, eliminating toxicity risks from traditional organic solvents.

An AAV vector delivers a mutated GIRK4 S143T channel to restore vision in rod-cone dystrophy patients despite high mutation variability and prior rod loss.

Selective S1PR2 antagonists reduce side effects by targeting specific receptors, improving treatment outcomes for fibrosis.

Chelated ferric pyrophosphate particles under 5 microns dissolve completely in dialysate, eliminating gastric irritation from iron supplements.

Bacterial composition maintains viability using silica and microcrystalline cellulose to control water activity.

Pressurized spray application resolves administration reliability contradictions while minimizing systemic thrombotic risks.